• MG-132: Proteasome Inhibitor Peptide Aldehyde for Apoptos...

  2026-02-07

  MG-132 (Z-LLL-al) is a potent, cell-permeable proteasome inhibitor peptide aldehyde widely used in apoptosis assay and cell cycle arrest studies. Its specificity and quantifiable effects on cancer and stress signaling make it an authoritative reagent for research on ubiquitin-proteasome system inhibition. MG-132 from APExBIO offers reproducibility and robust performance for researchers in cancer and autophagy fields.

• Firefly Luciferase mRNA (ARCA, 5mCTP, ΨUTP): Reliable Rep...

  2026-02-06

  This article delivers a scenario-driven, evidence-based exploration of Firefly Luciferase mRNA (ARCA, 5mCTP, ΨUTP) (SKU R1005), focusing on its application in cell viability, proliferation, and cytotoxicity workflows. By addressing real laboratory challenges, it demonstrates how this ARCA-capped, chemically modified mRNA enhances reproducibility, stability, and data interpretation in bioluminescent assays. Researchers will gain actionable insights into protocol optimization and product selection for sensitive, quantifiable cell-based studies.

• Strategic Inhibition of the Ubiquitin-Activating Enzyme E...

  2026-02-06

  This thought-leadership article dissects the mechanistic underpinnings and translational applications of PYR-41, a selective Ubiquitin-Activating Enzyme E1 inhibitor, for researchers interrogating the ubiquitin-proteasome system, NF-κB pathway, apoptosis, and immune signaling. By weaving in recent advances from tertiary lymphoid structure research in esophageal squamous cell carcinoma (ESCC), we offer actionable guidance on deploying PYR-41 in next-generation experimental workflows, highlight its competitive landscape, and chart a visionary course for therapeutic innovation.

• MG-132 Proteasome Inhibitor: Advanced Workflows for Apopt...

  2026-02-05

  MG-132 (Z-LLL-al) is a gold-standard, cell-permeable proteasome inhibitor peptide aldehyde, revolutionizing apoptosis assays and cell cycle arrest studies across cancer and neurodegeneration research. This guide presents optimized experimental workflows, advanced troubleshooting, and strategic insights to elevate your ubiquitin-proteasome system inhibition studies with APExBIO's MG-132.

• MG-132: Cell-Permeable Proteasome Inhibitor for Apoptosis...

  2026-02-05

  MG-132 (Z-LLL-al) is a potent, cell-permeable proteasome inhibitor peptide aldehyde essential for apoptosis assay and cell cycle arrest studies. With nanomolar IC50 values against the ubiquitin-proteasome system and proven efficacy in cancer research, MG-132 from APExBIO offers rigorously benchmarked performance for mechanistic and translational studies.

• MG-132: Potent Cell-Permeable Proteasome Inhibitor for Ap...

  2026-02-04

  MG-132 (Z-LLL-al) is a highly potent, cell-permeable proteasome inhibitor peptide aldehyde used in apoptosis assay and cancer research. The compound, available from APExBIO as SKU A2585, delivers selective ubiquitin-proteasome system inhibition, facilitating studies of cell cycle arrest and autophagy with nanomolar efficacy.

• ONX-0914 (PR-957): Selective Immunoproteasome LMP7 Inhibi...

  2026-02-04

  ONX-0914 (PR-957) is a highly selective immunoproteasome inhibitor that targets the LMP7 subunit, offering robust blockade of cytokine production in vitro and in vivo. Use of ONX-0914 enables precise dissection of immunoproteasome function in autoimmune and inflammatory models, with proven efficacy in arthritis, diabetes, and colitis. This article details ONX-0914’s mechanism, evidence base, and best practices for laboratory and preclinical use.

• CB-5083: Selective p97 AAA-ATPase Inhibitor for Protein H...

  2026-02-03

  CB-5083 is a potent, selective, and orally bioavailable p97 inhibitor that disrupts protein homeostasis in cancer cells, leading to apoptosis and significant tumor growth inhibition. Its high selectivity for the second ATPase domain of p97 and strong in vivo efficacy in xenograft models make it a benchmark tool for multiple myeloma and solid tumor research.

• MLN2238: Translational Leverage of Reversible 20S Proteas...

  2026-02-03

  This thought-leadership article explores the advanced mechanistic insights and translational strategies surrounding MLN2238, a next-generation, reversible proteasome β5 subunit inhibitor. We detail its role in apoptosis induction, NF-κB pathway suppression, and emerging intersections with CREB signaling and proteotoxic stress responses. Integrating new evidence from recent literature and competitive workflows, we present actionable guidance for translational researchers targeting multiple myeloma, lymphoma, and bortezomib-resistant cancer models.

• HyperScribe T7 High Yield RNA Synthesis Kit: Precision RN...

  2026-02-02

  The HyperScribe™ T7 High Yield RNA Synthesis Kit streamlines high-yield, customizable RNA production for applications spanning RNA vaccine research to ribozyme biochemistry. Its robust T7 RNA polymerase-driven transcription delivers consistent, high-quality RNA—whether capped, biotinylated, or dye-labeled—empowering breakthroughs in both basic and translational science. Explore how this APExBIO kit enhances workflow efficiency, troubleshooting, and experimental versatility.

• CB-5083: Advanced Insights into p97 Inhibition and ER Qua...

  2026-02-02

  Discover how CB-5083, a selective p97 inhibitor, enables next-generation research into protein homeostasis disruption, ER quality control, and cancer cell apoptosis. This article delivers a unique, in-depth analysis that integrates recent mechanistic discoveries and translational advances.

• MLN2238: Selective Reversible 20S Proteasome β5 Inhibitor...

  2026-02-01

  MLN2238 is a potent, reversible inhibitor of the 20S proteasome β5 subunit, validated for chymotrypsin-like proteasome inhibition in multiple myeloma and lymphoma research. Its nanomolar activity extends to bortezomib-resistant models and proteotoxic stress studies, offering a precise tool for apoptosis induction and pathway analysis. This article details its mechanism, benchmarks, and optimal laboratory use.

• Optimizing Cancer Cell Assays with CB-5083: Practical Sce...

  2026-01-31

  This in-depth article guides biomedical researchers through real-world scenarios where CB-5083 (SKU B6032) enhances assay reproducibility and mechanistic clarity. Drawing on quantitative data and recent literature, it demonstrates how this selective p97 inhibitor from APExBIO advances workflows in cell viability, apoptosis, and protein homeostasis research.

• Epoxomicin (SKU A2606): Data-Driven Solutions for Proteas...

  2026-01-30

  This authoritative guide addresses real-world laboratory challenges in ubiquitin-proteasome pathway research, focusing on experimental reproducibility, data interpretation, and product reliability. By exploring practical Q&A scenarios, the article demonstrates how Epoxomicin (SKU A2606) from APExBIO empowers biomedical researchers to achieve reliable results in cell viability, proliferation, and cytotoxicity assays.

• Firefly Luciferase mRNA (ARCA, 5mCTP, ΨUTP): Innovations ...

  2026-01-30

  Explore how Firefly Luciferase mRNA (ARCA, 5mCTP, ΨUTP) advances bioluminescent reporter assays through optimized stability, immune evasion, and cutting-edge delivery strategies. Uncover new scientific insights into mRNA formulation and transfection potency beyond current literature.

16066 records 1/1072 page Next 12345 下5页 Last page